⁹⁰Y‐ibritumomab‐tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single‐center experience

Abstract

Our retrospective single-center analysis of two patient groups without major differences in prognostic parameters revealed similar outcome with two different maintenance therapies. Hence, Y-ibritumomab-tiuxetan therapy might offer a valuable alternative treatment option for FL patients with partial response. However, large prospective trials are needed to confirm the reported findings.

Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience

“…Following the results of early clinical trials [6][7][8], 90 Y-IT was approved for treating recurrent or refractory iNHL in Japan. However, there has been only one retrospective study [9] and one preliminary result from a randomized phase II study comparing rituximab maintenance and RIT in patients with follicular lymphoma (FL) [10]. Therefore, we address the efficacy and safety of 90 Y-IT consolidation compared with those of rituximab maintenance in patients with iNHL.…”